<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03329560</url>
  </required_header>
  <id_info>
    <org_study_id>HSC-MS-17-0782</org_study_id>
    <nct_id>NCT03329560</nct_id>
  </id_info>
  <brief_title>Safety of FMT Using Oral Encapsulated PRIM-DJ2727 in HIV</brief_title>
  <official_title>Safety of Fecal Microbiota Transplant Using Oral Encapsulated PRIM-DJ2727 in HIV-infected Persons on Antiretroviral Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center, Houston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Texas Health Science Center, Houston</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether oral fecal microbiota transplantation (FMT)
      is safe for people with human immunodeficiency virus (HIV) infection.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 1, 2018</start_date>
  <completion_date type="Anticipated">February 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with adverse events related to study drug</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cumulative of adverse events related to study drug</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Severity of adverse events related to study drug</measure>
    <time_frame>24 weeks</time_frame>
    <description>Severity of adverse events will be based on Division of AIDS (DAIDS) grading criteria.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in the intestinal microbiome diversity as assessed by 16S rRNA sequencing</measure>
    <time_frame>week 0, week 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the intestinal microbiome abundance of genera as assessed by 16S rRNA sequencing</measure>
    <time_frame>week 0, week 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in systemic inflammation as assessed by interleukin 6 (IL-6) levels</measure>
    <time_frame>week 0, week 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in microbial translocation as assessed by soluble cluster of differentiation (CD14) levels</measure>
    <time_frame>week 0, week 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in gut barrier integrity as assessed by intestinal fatty acid binding protein (I-FABP)</measure>
    <time_frame>week 0, week 6</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">5</enrollment>
  <condition>HIV-1-infection</condition>
  <arm_group>
    <arm_group_label>Oral fecal microbiota transplantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects will receive one dose per week for 6 weeks (6 total doses) of PRIM-DJ2727 oral capsules containing lyophilized microbiota product derived from 150 grams of healthy donor stool.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Oral fecal microbiota transplantation</intervention_name>
    <description>All subjects will receive one dose per week for 6 weeks (6 total doses) of PRIM-DJ2727 oral capsules containing lyophilized microbiota product derived from 150 grams of healthy donor stool.</description>
    <arm_group_label>Oral fecal microbiota transplantation</arm_group_label>
    <other_name>PRIM-DJ2727</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV-1 infection, documented by any licensed HIV test

          -  Male subjects ≥ 18 years of age

          -  Identify as MSM (men who have sex with men)

          -  Currently on continuous ART for ≥96 weeks prior to study entry with no change in the
             ART regimen within the 24 weeks prior to study

          -  Ability and willingness of the participating subject to sign the informed consent form

          -  No plan to change ART regimen for the study duration

          -  Screening CD4+ cell count &gt;350 cells/mm3 obtained within 45 days prior to study entry

          -  HIV RNA &lt; 20 copies/ml for ≥24 weeks (1 blip of &lt; 500 copies/ml will be permitted)

          -  Absolute neutrophil count ≥ 1000 cells/mm3

        Exclusion Criteria:

          -  Initiation of ART during acute/early HIV infection (within 6 months of HIV
             seroconversion)

          -  Co-infection with Hepatitis B (positive HBsAg or positive HBcAb total with detectable
             HBV DNA levels) or Hepatitis C (positive HCV IgG with detectable HCV RNA levels)

          -  Use of antibiotics 60 days prior to the study entry

          -  Use of investigational therapies or vaccines 60 days prior to the study entry

          -  Serious illness requiring systemic treatment and/or hospitalization within 30 days
             prior to entry

          -  Cirrhosis, inflammatory bowel disease, total colectomy, colon or rectal anastomosis,
             bowel resection, or current colostomy

          -  Diabetes mellitus

          -  Any episode of acute or persistent diarrhea within 60 days prior to study entry

          -  Use of any of the following medications/products for more than 3 consecutive days
             within the 60 days prior to study entry: Immunosuppressives, Immune modulators,
             Antineoplastic agents (except for topical agents for skin cancer), Probiotics and
             prebiotics (supplements and products).
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Netanya S Utay, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Texas Health Science Center, Houston</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Netanya S Utay, MD</last_name>
    <phone>713-500-6700</phone>
    <email>Netanya.S.Utay@uth.tmc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Thomas Street Health Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77009</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Netanya S Utay, MD</last_name>
      <phone>713-500-6700</phone>
      <email>Netanya.S.Utay@uth.tmc.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 30, 2017</study_first_submitted>
  <study_first_submitted_qc>October 30, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 6, 2017</study_first_posted>
  <last_update_submitted>April 30, 2018</last_update_submitted>
  <last_update_submitted_qc>April 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Texas Health Science Center, Houston</investigator_affiliation>
    <investigator_full_name>Netanya Utay</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

